Results 121 to 130 of about 136,011 (340)

A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]

, 2008
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...
Biswas, S., Corrie, P., Dunn, Janet A., East, C., Hern, A., Lorigan, P., Marshall, A. (Andrea), Middleton, M. (Mark), Wrigley, J.   +8 more
core   +2 more sources

Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis

Frontiers in Pharmacology, 2023
Objective: To compare the efficacy and safety of treatments for patients with recurrent high-grade gliomas.Methods: Electronic databases including Pubmed, Embase, Cochrane Library and ClinicalTrials.gov were searched for randomized controlled trials (RCT)
Yanan Xu, Yanan Xu, Haijing Guan, Kefu Yu, Nan Ji, Zhigang Zhao, Zhigang Zhao   +6 more
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.

Journal of Clinical Oncology, 2020
PURPOSE A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have ...
C. Cremolini, C. Antoniotti, A. Stein, J. Bendell, T. Gruenberger, D. Rossini, G. Masi, E. Ongaro, H. Hurwitz, A. Falcone, H. Schmoll, M. Di Maio   +11 more
semanticscholar   +1 more source

FKB238: A Bevacizumab Biosimilar

Clinical Drug Investigation, 2021
FKB238 is a biosimilar of bevacizumab (a monoclonal antibody against vascular endothelial growth factor) approved for use in the same types of cancer as reference bevacizumab. FKB238 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic similarity was shown in healthy volunteers and in patients
openaire   +3 more sources

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data

Tumor Biology, 2017
To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy.
Meidan Liu, Yayuan Zheng, Zuguang Chen, Yumiao Qiu, Zhanchun Pan, Zitao Cai, Yapeng Shi, Junfen Cheng, Weimin Yao   +8 more
doaj   +1 more source

Bevacizumab in maintenance therapy for ovarian cancer patients

Южно-Российский онкологический журнал, 2020
Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF).
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, E. V. Verenikina, S. N. Kabanov, Ya. V. Svetitskaya, N. Yu. Samaneva, N. M. Tikhanovskaya, K. A. Novoselova, O. G. Selezneva, A. V. Tishina   +10 more
doaj   +1 more source

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]

, 2013
BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hong, David S, Jiang, Yunfang, Kurzrock, Razelle, Morgan-Linnell, Sonia K, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +2 more sources

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Journal of Clinical Oncology, 2014
PURPOSE In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-
E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, G. Kristensen, R. Sorio, I. Vergote, P. Witteveen, A. Bamias, D. Pereira, P. Wimberger, A. Oaknin, M. Mirza, P. Follana, D. Bollag, I. Ray-Coquard   +16 more
semanticscholar   +1 more source

Clinical significance of preoperative Glasgow prognostic score in patients with colorectal cancer and synchronous peritoneal metastases

Annals of Gastroenterological Surgery, EarlyView.
Preoperative GPS2 is an independent poor prognostic factor in patients with colorectal cancer and synchronous peritoneal metastases, and surgical resection does not improve prognosis in patients with GPS2. Preoperative GPSs may be used as indicators for surgical resection of synchronous peritoneal metastases.
Kosuke Fujimoto, Fumikazu Koyama, Hirotoshi Kobayashi, Kenjiro Kotake, Masayasu Kawasaki, Yukihide Kanemitsu, Yusuke Kinugasa, Hideki Ueno, Kotaro Maeda, Takeshi Suto, Michio Itabashi, Kimihiko Funahashi, Heita Ozawa, Shingo Noura, Hideyuki Ishida, Masayuki Ohue, Tomomichi Kiyomatsu, Soichiro Ishihara, Keiji Koda, Hideo Baba, Kenji Kawada, Yojiro Hashiguchi, Takanori Goi, Yuji Toiyama, Naohiro Tomita, Eiji Sunami, Fumihiko Fujita, Jun Watanabe, Kenichi Hakamada, Goro Nakayama, Kenichi Sugihara, Yoichi Ajioka   +31 more
wiley   +1 more source